肺高血压会损害大鼠腹膜动脉的血管运动功能
Kiana M Schulze1, Andrew G Horn1, Judy M Muller-Delp2
1Department of Kinesiology, Kansas State University, Manhattan, KS 66506, United States of America.
Microvascular research
|April 13, 2024
概括
肺高血压会损害隔膜血管功能,减少氧气供应,并导致运动不耐受. 这项研究发现,在肺高血压大鼠中,血管扩张和肌源性反应减弱.
科学领域:
- 心血管生理学心血管生理学
- 呼吸系统生理学 呼吸系统生理学
- 血管生物学 血管生物学
背景情况:
- 肺高血压 (PH) 导致呼吸道肌肉功能障碍,导致运动不耐受和呼吸障碍.
- 腹膜收缩功能,血液流动和高血压在PH患者中发生变化.
- 隔膜阻力血管系统中血管活性受损可能导致这些变化.
研究的目的:
- 为了研究肺高血压导致内皮依赖血管扩张变和膜动脉小动脉中肌体反应能力受损的假设.
- 确定血管功能障碍在隔膜对肺高血压反应中的作用.
主要方法:
- 雌性Sprague-Dawley大鼠被诱导使用单色他 (MCT) 来创建肺高血压模型.
- 实验中使用了健康对照 (HC) 和MCT大鼠 (每只n=9) 来进行实验.
- 从中间肋间隔膜中分离出第一阶段动脉小管 (1A),并在体外研究血管扩张和肌原反应.
主要成果:
- 与HC大鼠 (78 ± 15%) 相比,MCT大鼠 (47 ± 17%) 通过乙胆显著减少了依赖内皮的血管扩张.
- 与HC大鼠 (89 ± 10%) 相比,MCT大鼠 (66 ± 10%) 的内皮独立血管扩张通过酸也显著减少.
- 由MCT诱导的PH减少了肌体收缩,但没有影响隔膜动脉小管中的被动压力反应.
结论:
- 隔膜血管功能障碍,影响内皮依赖和独立的机制,有助于隔膜软弱和肺高血压中受损的高血压.
- 由于血管功能障碍,对隔膜的氧气输送受损是与PH相关的运动不耐受的一个关键因素.
- 这些发现强调了解决腹膜血管健康问题的重要性,以管理肺高血压并发症.
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
173
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
173
Antihypertensive Drugs: Vasodilators
516
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
516


